New Research May Explain Why Obese People Have Higher Rates of Asthma
Embargo expired: 1/8/2013 12:00 PM EST
Source Newsroom: Columbia University Medical Center
Findings suggest that therapies that increase leptin-signaling may relieve asthma in obese people
Newswise — New York, NY — A new study led by Columbia University Medical Center (CUMC) researchers has found that leptin, a hormone that plays a key role in energy metabolism, fertility, and bone mass, also regulates airway diameter. The findings could explain why obese people are prone to asthma and suggest that body weight–associated asthma may be relieved with medications that inhibit signaling through the parasympathetic nervous system, which mediates leptin function. The study, conducted in mice, was published in the online edition of the journal Cell Metabolism.
“Our study started with the clinical observation that both obesity and anorexia can lead to asthma,” said Gerard Karsenty MD, PhD, professor and chair of genetics and development and professor of medicine at CUMC, and lead author of the study. “This led us to suspect that there must be a signal coming from fat cells that somehow affects the lungs —directly or indirectly.” The most likely candidate was leptin, a protein made by fat cells that circulates in the bloodstream and travels to the brain.
Extensive evidence shows that obesity can cause narrowing of the airways (bronchoconstriction). When obesity develops in people with asthma, it exacerbates the breathing disorder and hampers its treatment through mechanisms that are poorly understood. The current study was designed to elucidate the genetic and molecular bases of the relationships among obesity, airway diameter, and lung function.
Through mouse studies, the researchers showed that abnormally low or high body weight and fat mass results in bronchoconstriction and diminished lung function. Next, they showed that leptin increases airway diameter independently of, and at a lower threshold than, its regulation of appetite.
Leptin affects the airways by decreasing the activity of the parasympathetic nervous system, a branch of the autonomic nervous system not usually associated with leptin. The researchers also showed that regulation of airway diameter occurs regardless of local inflammation in the bronchi.
The researchers conducted two subsequent experiments to determine if these findings might have bearing on asthma therapy. In one, they took obese, asthmatic mice and administered a substance that increases lung inflammation. When they infused leptin in the brain of these mice for four days, “There was no effect on inflammation, but airway diameter and lung functions were normal,” said Dr. Karsenty. “This showed that, at least in the mouse, you can cure obesity-related asthma without affecting inflammation.” In the second experiment, the researchers treated obese, asthmatic mice with drugs that decrease parasympathetic tone, or rate of neuronal firing. Again, the asthma abated after several days.
“The therapeutic implication is that it may be possible to correct asthma in obese people with drugs that inhibit parasympathetic signaling—and thereby inhibit leptin deficiency-related brain signaling,” said Dr. Karsenty. Such drugs are already available. One is tiotropium bromide (Spiriva®, manufactured by Boehringer Ingelheim Pharmaceuticals, Inc.), which is used primarily for the treatment of chronic obstructive pulmonary disease. Clinical trials are needed before this or a more active and selective drug can be recommended for the treatment of body weight–associated asthma, Dr. Karsenty added.
The title of the paper is “Inhibition of leptin regulation parasympathetic signaling as a cause of extreme body weight associated asthma.” The other contributors are Emilio Arteaga-Solis, Tiffany Zee, Charles W. Emala (CUMC); and Charles Vinson, and Jürgen Wess (NIH).
The study was supported by the John M. Driscoll, Jr., MD, Children’s Fund Scholars, the Irving Institute/Clinical Trials Office Pilot Award, and the National Institutes of Health (RO1 DK58883).
The authors declare no financial or other conflicts of interest.
Columbia University Medical Center provides international leadership in basic, pre-clinical, and clinical research; medical and health sciences education; and patient care. The medical center trains future leaders and includes the dedicated work of many physicians, scientists, public health professionals, dentists, and nurses at the College of Physicians and Surgeons, the Mailman School of Public Health, the College of Dental Medicine, the School of Nursing, the biomedical departments of the Graduate School of Arts and Sciences, and allied research centers and institutions. Established in 1767, Columbia's College of Physicians and Surgeons was the first institution in the country to grant the MD degree and is among the most selective medical schools in the country. Columbia University Medical Center is home to the largest medical research enterprise in New York City and State and one of the largest in the United States. Its physicians treat patients at multiple locations throughout the tri-state area, including the NewYork-Presbyterian/Columbia campus in Washington Heights, the new ColumbiaDoctors Midtown location at 51 W. 51st St. in Manhattan, and the new ColumbiaDoctors Riverdale practice. For more information, visit www.cumc.columbia.edu or columbiadoctors.org.